FDA Approved: * March 16, 2020
Pharm Company: * APOTEX INC
Category: Cancer

Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.[2] It was developed by Onyx Pharmaceuticals. The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012, for use in people with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as le... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Related Brands

Drugs with the same active ingredients